Clinacin 25 mg Tablets

Ülke: İrlanda

Dil: İngilizce

Kaynak: HPRA (Health Products Regulatory Authority)

Aktif bileşen:

Clindamycin (as clindamycin hydrochloride)

Mevcut itibaren:

Chanelle Animal Health Ltd.

ATC kodu:

QJ01FF01

INN (International Adı):

Clindamycin (as clindamycin hydrochloride)

Doz:

25 mg/tablet

Farmasötik formu:

Tablet

Reçete türü:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapötik grubu:

Cats, Dogs

Terapötik alanı:

clindamycin

Terapötik endikasyonlar:

Antibacterial

Yetkilendirme durumu:

Authorised

Yetkilendirme tarihi:

1999-10-29

Ürün özellikleri

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clinacin 25 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Clindamycin 25 mg
(as Clindamycin hydrochloride)
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Tablet.
A small round white tablet with a break-line on one side and the
letter J embossed on both sides of the breakline.
The
tablets can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and Cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Clinacin 25 mg Tablets are antibiotics indicated for the treatment of
infected wounds, abscesses, pyoderma and oral
cavity/dental infections caused by or associated with
clindamycin-sensitive staphylococci, streptococci, bacteroidaceae,
_Fusobacterium necrophorum, Clostridium perfringens_ and osteomyelitis
caused by_ Staphylococcus aureus._
Clinacin 25
mg Tablets can also be used to help provide antimicrobial cover during
dental procedures.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to clindamycin or lincomycin.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_0_
_/_
_1_
_1_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_4_
_8_
_7_
_0_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged osteomyelitis therapy of one month or greater,
periodic liver and kidney funct